Subscribe
shutterstock_705090544_zerbor
Zerbor / Shutterstock.com
6 January 2020AmericasRory O'Neill

Judge approves $120m Momenta and Sandoz settlement

A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against  Momenta Pharmaceuticals and  Sandoz over their alleged manipulation of drug testing protocols.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Ex-Sandoz exec pleads guilty to price fixing in generics probe
18 February 2020   Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.
Big Pharma
Sandoz and Momenta to pay $120m to end antitrust suit
24 December 2019   Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.
Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Generics
Ex-Sandoz exec pleads guilty to price fixing in generics probe
18 February 2020   Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.
Big Pharma
Sandoz and Momenta to pay $120m to end antitrust suit
24 December 2019   Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.
Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

More on this story

Generics
Ex-Sandoz exec pleads guilty to price fixing in generics probe
18 February 2020   Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.
Big Pharma
Sandoz and Momenta to pay $120m to end antitrust suit
24 December 2019   Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.
Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB